Bioventus Inc. Class A Common Stock (BVS) — 分析摘要
Bioventus Inc. Class A Common Stock（BVS）的市值为892.24百万美元，最近一年的营收同比增长了-0.9%。净利润率为4.0%。当前市盈率为31.3倍。
核心要点
- 营收同比变化-0.9%
- 净利润率4.0%
- 市盈率31.3倍
与SURGICAL & MEDICAL INSTRUMENTS & APPARATUS板块的其他公司相比，BVS的营收增长为-0.9%，市盈率为31.3倍。
Bioventus Inc. Class A Common Stock (BVS)
更新 — ET · 来源 POLYGON
红旗与风险提示无重大红旗
基于最新财报，没有触发重大的信用、利润率或趋势红旗。
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
行业
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
员工人数
940
总部
DURHAM, NC
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
N/A
股息收益率
N/A
股息历史
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。